FDA approves Merck’s anti-PD-1 therapy for endometrial carcinoma patients

FDA approves Merck’s anti-PD-1 therapy for endometrial carcinoma patients

Submitted by admin on March 22, 2022 - 10:41am
Source: 
Pharmaceutical Business Review
News Tags: 
Merck
Keytruda
endometrial cancer
FDA
Headline: 
FDA approves Merck’s anti-PD-1 therapy for endometrial carcinoma patients
snippet: 

The US Food and Drug Administration (FDA) has approved Merck’s anti-PD-1 therapy, Keytruda, to treat advanced endometrial carcinoma patients.

Do Not Allow Advertisers to Use My Personal information